Similar beneficial effects were reported for liraglutide, an once-daily glucagon-like peptide-1 receptor agonist (GLP-1 RA), and for semaglutide, an once-weekly GLP-1 RA, both of which reduced CVD morbidity and mortality (but not hospitalization for HF) in T2D patients with established CVD, in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial [9] and the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) [11], respectively. Here, GLP1R is linked to hydrops fetalis.